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This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).SUMMARYStandardization of mesenchymal stromal cells (MSCs) is hampered by the lack of a precise definition for these cell preparations; for
example, there are no molecular markers to discern MSCs and fibroblasts. In this study, we followed the hypothesis that specific
DNA methylation (DNAm) patterns can assist classification of MSCs. We utilized 190 DNAm profiles to address the impact of tissue
of origin, donor age, replicative senescence, and serum supplements on the epigenetic makeup. Based on this, we elaborated a simple
epigenetic signature based on two CpG sites to classify MSCs and fibroblasts, referred to as the Epi-MSC-Score. Another two-CpG
signature can distinguish between MSCs from bone marrow and adipose tissue, referred to as the Epi-Tissue-Score. These assays
were validated by site-specific pyrosequencing analysis in 34 primary cell preparations. Furthermore, even individual subclones
of MSCs were correctly classified by our epigenetic signatures. In summary, we propose an alternative concept to use DNAm patterns
for molecular definition of cell preparations, and our epigenetic scores facilitate robust and cost-effective quality control of MSC
cultures.INTRODUCTION
Mesenchymal stromal cells (MSCs) are currently tested for
a wide range of clinical applications (Squillaro et al., 2015),
but there are no precise measures for their quality control.
Molecular markers to clearly discern MSCs and fibroblasts
remain elusive. The major difference between these two
cell types is that particularly MSCs comprise a multipo-
tent subset often referred to as ‘‘mesenchymal stem cells’’
(Dominici et al., 2006). Several surface markers have been
suggested for enrichment of MSCs, such as CD106,
CD146, and CD271 (Buhring et al., 2007; Halfon et al.,
2011; Sorrentino et al., 2008), but none of them seems
to be exclusively expressed on MSCs. Proteomics and
gene-expression profiles can discern cells that have been
obtained from different tissues or under different culture
conditions (Holley et al., 2015; Ishii et al., 2005), and
high-content screening assays based on microRNA or
RNAi can elucidate cell type-specific responses (Bae et al.,
2009; Erdmann et al., 2015). However, all these profiling
and high-throughput techniques are relatively time and
labor consuming, require complex computational analysis,
and can hardly be standardized for quality control of MSC
preparations.
Cellular differentiation is reflected by specific epigenetic
patterns. DNA methylation (DNAm) is the best charac-168 Stem Cell Reports j Vol. 6 j 168–175 j February 9, 2016 j ª2016 The Auterized epigenetic modification, where cytosine guanine
dinucleotides (CpGs) are covalently methylated at the
cytosine residue (Jaenisch and Bird, 2003). DNAm has
several advantages as a biomarker for classification of cell
preparations: (1) it is rather stable; (2) it facilitates quantita-
tive analysis at single-nucleotide resolution, and (3) it is
directly coupled to cellular differentiation (Karnik and
Meissner, 2013). We have recently described that DNAm
levels at twoCpGs can reliably discern between pluripotent
and non-pluripotent cells (Lenz et al., 2015). In this study,
we followed the hypothesis that the DNAmprofile ofMSCs
might also reflect specific modifications that are indicative
for the cell type and/or the tissue of origin. Small epigenetic
signatures based on site-specific analysis of DNAm in a few
CpG sites might therefore be particularly appealing for the
classification of MSCs.RESULTS
Global Comparison of DNA Methylation Profiles
We compiled a well-curated dataset of publicly available
DNAm profiles that were generated on the Illumina Hu-
manMethylation BeadChip platforms: 83 DNAm profiles
analyzed on 27K BeadChips were used as a training set;
and 107 DNAm profiles of 450K BeadChips were used asthors
Figure 1. Differentially Methylated CpGs in Pairwise
Comparisons
DNA methylation profiles (generated on Illumina Human-
Methylation BeadChips 27K or 450K) were stratified by cell type
(MSCs versus fibroblasts), tissue source (here particularly MSCs
from bone marrow versus adipose tissue), passage (<P5 or >P5),
age (<40 or >40 years), and serum supplements in culture media
(human platelet lysate [hPL] versus fetal calf/bovine serum [FBS]).
The number of DNAm profiles per group is indicated (n) as well as
the number of significant CpGs (adjusted limma t test: p < 0.05 and
>10% difference in mean DNAm). Overlapping CpGs in the 27K and
450K datasets are indicated by black bars.independent validation sets (Tables S1 and S2). Therefore,
we focused on 25,014 CpGs that were represented by
both platforms. Initially, we performed principal-compo-
nent analysis (PCA) to estimate the impact of cell typeStem Ce(MSCs or fibroblasts), tissue source (bone marrow [BM],
adipose tissue [AT], lung, dermis, etc.), age (stratified by
40 years), passage (stratified by P5), or serum supplement
(human platelet lysate [hPL] versus fetal calf/bovine serum
[FBS]) on the global DNAm patterns. However, none of
the major PCA components could clearly classify cell
preparations according to these parameters, and there
was only a moderate tendency in the comparisons: MSCs
versus fibroblasts, and MSCs derived from BM versus AT
(Figure S1).
Subsequently, we determined the number of differen-
tially methylated CpGs in pairwise comparisons (adjusted
limma t test: p < 0.05 and at least 10% differential DNAm
level). This was performed independently for the 27K-
BeadChip training and the 450K-BeadChip validation
set. To roughly estimate the reproducibility of DNAm dif-
ferences, we then focused on CpGs with overlapping
DNAm changes in both datasets (Figure 1): 346 and 152
CpGs were methylated higher in MSCs and fibroblasts,
respectively, indicating that there are reproducible epige-
netic differences between the two cell types. Furthermore,
580 and 307 CpGs were differentially methylated in
MSCs from BM versus AT. There were hardly any overlap-
ping age-related DNAm differences in samples from
younger or older donors, although it has been shown
that age-related DNAm patterns persist in MSCs (Frobel
et al., 2014; Weidner et al., 2014). This might be due to
the classification into two age groups, whereas age-related
changes are continuously acquired throughout life. In
analogy, we observed only 242 CpGs that were methyl-
ated higher at early passages (<P5) compared with late
passages (>P5), although many DNAm changes were
shown to be continuously hyper- and hypomethylated
during culture expansion (Koch et al., 2013). Serum sup-
plements seemed to induce rather few DNAm changes.
Taken together, global analysis indicated that particularly
cell type and tissue of origin are reflected by specific
DNAm changes.
Epigenetic Score for Classification into MSCs and
Fibroblasts
To identify CpGs that facilitate the best discrimination
of MSCs and fibroblasts in the 27K-BeadChip training
set, we selected CpGs with (1) the highest difference in
mean DNAm in MSCs versus fibroblasts, and (2) small
variation in DNAm levels within each of the two cell
types (Figure 2A). Only three and nine CpGs revealed
more than 40% higher DNAm levels in MSCs and fibro-
blasts, respectively (Figure 2B). These CpGs were subse-
quently plotted against the sum of variances in MSCs
and fibroblasts, and thereby we identified four candidate
CpGs that were associated with serpin peptidase inhibitor
B5 (SERPINB5: cg00226904), chromosome 3 open readingll Reports j Vol. 6 j 168–175 j February 9, 2016 j ª2016 The Authors 169
Figure 2. Epigenetic Classification of MSCs and Fibroblasts
(A) Schematic overview of the experimental design that led to the Epi-MSC-Score.
(B) Scatterplot of mean DNAm levels of MSCs and fibroblasts in the training dataset (CpGs with more than 40% difference are indicated by
red lines).
(C) Differential DNAm levels were plotted against the sum of variances within MSCs and fibroblasts.
(D) DNAm levels (b values) of four CpGs that have been selected from the training datasets (27K BeadChips).
(E) Classification of the training dataset by the Epi-MSC-Score. This score represents the difference of b values at cg22286764 (C3orf35)
and cg05684195 (CIDEC).
(F) DNAm levels of the four selected CpGs in the validation dataset (450K BeadChips; in analogy to Figure 2D).
(G) Classification of the validation dataset by the Epi-MSC-Score.
(H) Pyrosequencing analysis of DNAm at the two CpGs corresponding to the Epi-MSC-Score in 34 different cell preparations.
(I) Classification of pyrosequencing results by the Epi-MSC-Score based on CpG in C3orf35 and CIDEC as indicated.frame 35 (C3orf35: cg22286764), cell death-inducingDFFA-
like effectorC (CIDEC: cg05684195), and adipocyte-specific
adhesion molecule (ASAM: cg19096475; Figures 2C and170 Stem Cell Reports j Vol. 6 j 168–175 j February 9, 2016 j ª2016 The Au2D). Iterative pair combinations of these CpGs demon-
strated that the difference in DNAm at the CpGs
in C3orf35 and CIDEC, subsequently referred to as thethors
Epi-MSC-Score, could best discern MSCs from fibro-
blasts: a positive score is indicative of MSCs and 96% of
samples were correctly classified in the 27K-BeadChip
training set (Figure 2E). We repeated the analysis after
resampling the training set with bootstrapping, and the
two CpGs were among the top eight stable CpG sites (Sup-
plemental Experimental Procedures). In the independent
450K-BeadChip validation set, all four candidate CpGs re-
vealed the same trend (Figure 2F) and 83% of the samples
were classified correctly (Figure 2G). Overall the differences
in mean DNAm levels in MSCs versus fibroblasts were
smaller in this dataset. However, applying the two afore-
mentioned criteria for selection of relevant CpGs on the
450K dataset demonstrated that the two CpGs in C3orf35
and CIDEC were again among the best performing (data
not shown).
We then designed pyrosequencing assays for these two
regions to facilitate robust and more quantitative analysis
of the DNAm levels at the two relevant CpG sites (Fig-
ure S2A). These pyrosequencing assays were tested on
34 primary cell preparations, all of which were correctly
classified into MSCs and fibroblasts (Figures 2H and 2I).
Gene-expression profiles demonstrated slightly higher
expression of C3orf35 and CIDEC in MSCs (Figure S2B).
Thus, the Epi-MSC-Score can be used for the classification
of MSCs and fibroblasts.
Epigenetic Score to Discern MSCs from Bone Marrow
and Adipose Tissue
We extended this analysis to derive an ‘‘Epi-Tissue-Score’’
for discerning MSCs that were initially isolated from
either BM or AT, since these tissues are most frequently
used for isolation of MSCs (Figure 3A). 29 and 30 CpGs
revealed a more than 40% higher mean DNAm level in
MSCs from either BM or AT, respectively (Figure 3B).
We focused on 12 CpGs with lowest variances within
each of these groups, which were associated with: solute
carrier family 41 magnesium transporter member 2
(SLC41A2: cg27149093); single-minded family BHLH
transcription factor 2 (SIM2: cg02672220); four and a
half LIM domains 2 (FHL2: cg10635061); transmembrane
4 six family member 1 (TM4SF1: cg08124030); src-like-
adaptor (SLA: cg02794695); runt-related transcription
factor 1 (RUNX1: cg19836199); guanylate cyclase 1, solu-
ble, beta 2 (GUCY1B2: cg16692277); urocortin 2 (UCN2:
cg05125838); interleukin-26 (IL26: cg25697314); eco-
tropic viral integration site 2B (EVI2B: cg05109049);
tubulin tyrosine ligase-like family member 3 (TTLL3:
cg03375833); and intestinal trefoil factor 3 (TFF3:
cg04806409; Figures 3C and 3D). The difference between
the DNAm levels of the CpGs in SLC41A2 and TM4SF1
showed best discrimination in the 27K-BeadChip
training set (100% correctly classified) and was thereforeStem Ceconsidered as the Epi-Tissue-Score (Figure 3E). Notably,
all 12 candidate CpGs demonstrated tissue type-specific
DNAm patterns also in the 450K-BeadChip validation
set (Figure 3F), and 98.4% of these samples were correctly
classified by the Epi-Tissue-Score (Figure 3G). Pyrose-
quencing assays were designed for the two CpGs
in SLC41A2 and TM4SF1 (Figure S3A), and thereby
22 analyzed MSC preparations were correctly classified
into BM- or AT-derived MSCs (Figures 3H and 3I). We
also observed moderate differences in gene expression
of SLC41A2 and TM4SF1 between MSCs from BM
and AT (Figure S3B). Our analysis pinpoints clear molec-
ular differences in MSCs that have been isolated
from BM or AT, which can be reliably tracked by the
Epi-Tissue-Score.
Epigenetic Classification of iPSC-Derived MSCs
We have recently demonstrated differentiation of in-
duced pluripotent stem cells (iPSCs) toward MSCs,
referred to as iPS-MSCs (Frobel et al., 2014). The DNAm
profiles of these iPS-MSCs were now compared with
those of primary cell preparations: iPS-MSCs were classi-
fied as MSCs by the Epi-MSC-Score (Figures S4A and S4B),
and this was validated by pyrosequencing analysis of
additional iPS-MSC preparations (Figure S4F). In contrast,
the DNAm patterns at the 12 tissue-specific CpGs were
not clearly indicative of BM- or AT-derived MSCs (Fig-
ure S4C). PCA analysis using either the four cell type-spe-
cific or the 12 tissue-specific CpGs supported the notion
that iPS-MSCs are related to MSCs, whereas they do not
reflect a clear tissue-specific association (Figures S4D
and S4E). This is in line with our previous report that
tissue-specific patterns are erased by reprogramming
into iPSCs (Shao et al., 2013), and overall are not reestab-
lished upon differentiation of iPSCs toward MSCs (Frobel
et al., 2014).
Epigenetic Classification of Subclones
Mesenchymal stem cells comprise heterogeneous subpop-
ulations (Cai et al., 2014; Schellenberg et al., 2012), and
we have therefore challenged our epigenetic signatures
on subclones. MSC cultures were seeded in 96-well plates
in limiting dilutions and analyzed after 2 weeks. Additional
96-well plates were further differentiated toward adipo-
genic or osteogenic lineages for 2 weeks (Figure S4G). The
individual subclones revealed very heterogeneous in vitro
differentiation potential, as described in our previous
work (Schellenberg et al., 2012), and could therefore be
classified into clones with high or low differentiation po-
tential (Figure 4A). Adipogenic differentiation potential
was estimated by the percentage of cells harboring fat drop-
lets (stained with BODIPY) and osteogenic differentiation
by the amount of calcium phosphate precipitates (stainedll Reports j Vol. 6 j 168–175 j February 9, 2016 j ª2016 The Authors 171
Figure 3. Classification of MSCs from Bone Marrow and Adipose Tissue
(A) Schematic overview of experimental design that led to the Epi-Tissue-Score.
(B) Scatterplot of mean DNAm levels in MSCs from bone marrow (BM) versus MSCs from adipose tissue (AT) in the training set
(27K BeadChips; CpGs with more than 40% difference are indicated by red lines).
(C) Differential DNAm levels were plotted against the sum of variances within MSCs derived from either BM or AT.
(D) b Values (DNAm levels) of 12 CpGs that were selected by these criteria.
(E) Classification of the training dataset by the Epi-Tissue-Score. This score represents the difference of b values at cg27149093 (SLC41A2)
and cg08124030 (TM4SF1).
(F) DNAm levels of the 12 selected CpGs in the validation dataset (450K BeadChips; in analogy to Figure 3D).
(G) Classification of the validation dataset by the Epi-Tissue-Score.
(H) Pyrosequencing analysis of DNAm at the two CpGs corresponding to the Epi-Tissue-Score in 22 MSC samples from BM and AT.
(I) Classification of pyrosequencing results by the Epi-Tissue-Score based on CpG in SLC41A2 and TM4SF1 as indicated.with Alizarin red; Figure 4B). DNA of 30 clones was subse-
quently harvested and analyzed with our Epi-MSC-Score
and Epi-Tissue-Score. All subclones were correctly classified172 Stem Cell Reports j Vol. 6 j 168–175 j February 9, 2016 j ª2016 The Auas BM-derived MSCs, irrespective of their in vitro differen-
tiation potential (Figures 4C, 4D, S4H, and S4I). This indi-
cates that the epigenetic classification is not due to shiftsthors
Figure 4. Analysis of Epigenetic Scores in
Subclones of MSCs
(A) Bone marrow-derived MSCs were subcl-
oned and differentiated toward adipo-
genic or osteogenic lineages (stained with
BODIPY/DAPI or Alizarin red, respectively).
Representative images of clones with low or
high differentiation potential are shown.
(B) The in vitro differentiation potential
toward adipogenic and osteogenic lineages
was determined based on the percentage
of cells with fat droplets or absorbance of
Alizarin staining, respectively. For subse-
quent pyrosequencing analysis, we selected
five clones that revealed either higher or
lower differentiation (Student’s t test; *p <
0.05; error bars represent the SD).
(C and D) Classification of MSC clones based
on pyrosequencing results by Epi-MSC-Score
(C) and Epi-Tissue-Score (D).in the cellular composition, and rather reflects cell-intrinsic
molecular characteristics.DISCUSSION
Reliable measures for quality control are a prerequisite for
the standardization of cell preparations to be used in exper-
imental studies and cellular therapy. Here, we demonstrate
that epigenetic signatures can support the classification
of MSCs. In general, the precision of signatures can be
increased by using a higher number of CpGs, but this re-
quires more complex or even genome-wide analysis. Our
two CpGs scores, which are based on one hypermethylated
and one hypomethylated CpG site, are therefore a
tradeoff to facilitate fast, cost-effective, and transparent
classification.
Despite extensive efforts, it remains a challenge to distin-
guish between fibroblasts andMSCs. This definition is usu-
ally based on the in vitro differentiation potential of MSCs,
although these surrogate assays hardly facilitate quan-
titative comparison, particularly not between different
laboratories (Bortolotti et al., 2015; Dominici et al., 2006;
Hematti, 2012). In our comparative study, we had to rely
on the classificationprovided by the authorswhodeposited
the DNAm profiles. Hence, they are not based on common
standards in cell culture and quality control. At least for theStem Cecell preparations that we analyzed by pyrosequencing,
we consistently observed higher differentiation potential
in MSCs compared with fibroblasts (Koch et al., 2011),
and these were all correctly classified by the Epi-MSC-
Score. On the other hand, our clonal analysis indicated
that this signature is not directly associated with the subset
in MSCs that reveals higher in vitro differentiation
potential.
The epigenome reflects the tissue of origin even after
long-term culture (Reinisch et al., 2015; Schellenberg
et al., 2012). MSCs can be isolated from a multitude of
different tissues (Crisan et al., 2008), but the vast majority
of studies utilize MSCs from BM and AT. In fact, cell prepa-
rationsderived fromother tissues areoften rather referred to
as fibroblasts, and therefore classification of the Epi-MSC-
Score may partly be also attributed to the different tissue
sources. Either way, classifications with the Epi-MSC-Score
are generally in linewith those provided by the correspond-
ing publications. Furthermore, the Epi-Tissue-Score can
very reliably distinguish between MSCs from BM and AT.
The remarkable difference in the epigenetic makeup of
MSCs from different tissues, which are cell intrinsic and
not due to cellular heterogeneity, may reflect the stark tis-
sue-specific differences in gene-expression profiles (Wagner
et al., 2005), proteome (Wagner et al., 2006), and functional
readouts (Reinisch et al., 2015). All the more, such analysis
is relevant for quality control.ll Reports j Vol. 6 j 168–175 j February 9, 2016 j ª2016 The Authors 173
Researchers are usually aware of the tissue that was
initially used for isolation of MSCs, but there is evidence
that accidental interchange of samples or contaminations
with other cells can occur (Garcia et al., 2010; Torsvik
et al., 2010). For established cell lines, some contamina-
tions can be detected by specific SNPs or mutations, but
for primary cells with unknown genetic background this
can hardly be unraveled. In this regard, our epigenetic
signatures provide a perspective for quality control of cell
preparations. We expect that the signatures can be further
fine-tuned based on the rapidly growing number of avail-
able DNAm datasets. This will also facilitate generation of
other epigenetic signatures reflecting functional properties
ofMSCs, such as their immunomodulatory potential or the
hematopoiesis supportive function (Wuchter et al., 2015).
It is even conceivable that epigenetic signatures can be
developed to estimate the therapeutic potential of MSCs,
but such predictors need to be specifically trained and vali-
dated on suitable datasets. In this regard, our exploratory
study provides an alternative concept for the definition,
characterization, and classification of MSCs.EXPERIMENTAL PROCEDURES
A detailed description of all Experimental Procedures used is pre-
sented in Supplemental Experimental Procedures.DNA Methylation Datasets
Illumina Human Methylation BeadChip datasets (27K or 450K) of
MSCs and fibroblasts were retrieved from the NCBI Gene Expres-
sion Omnibus (Tables S1 and S2).Derivation of Epigenetic Scores
To identify the best suited biomarkers for classification, we selected
CpG sites with high differences in mean DNAm levels (>40% of
difference) and low variance within groups. A hypermethylated
and a hypomethylated CpG were then utilized for each score as
follows: Epi-MSC-Score = b value at cg22286764 (C3orf35) minus
the b value at cg05684195 (CIDEC); and Epi-Tissue-Score = b value
at cg27149093 (SLC41A2) minus the b value at cg08124030
(TM4SF1). Both scores range from1 to 1; positive values indicate
MSCs and BM, and negative ones fibroblast and AT, respectively.Primary Cells
All cellswere taken afterwrittenconsentwas granted, andhavebeen
specifically approved by the local Ethics Committees for Use of
Human Subjects at RWTH Aachen University (permit numbers:
BM-MSC: #EK128/09; AT-MSCs: #EK187/08; fibroblasts: #EK187/
08). Cell culture, immunophenotyping, and in vitro differentiation
were performed as described previously (Frobel et al., 2014; Koch
et al., 2011). Additional Information about the samples is provided
inTable S3. For clonal analysis,MSCs at passage 1–2 (n= 3)were sub-
mitted to the limiting dilutions in 96-well plates of 1, 3, 10, and 30
cells per well as described previously (Schellenberg et al., 2012).174 Stem Cell Reports j Vol. 6 j 168–175 j February 9, 2016 j ª2016 The AuPyrosequencing Analysis
Genomic DNA was isolated from 106 cells (bulk culture) or clones
in 96-well plates using the NucleoSpin Tissue/Tissue XS kits
(Macherey-Nagel) and quantified with an ND-1000 spectrometer
(NanoDrop). Between 100 and 1,000 ng of DNAwas sodium bisul-
fite-converted using the EZ DNAMethylation kit (Zymo Research),
and PCR procedures and sequencing assays were performed using
the PyroMark PCR and Q96 kits (Qiagen) (Lenz et al., 2015).
Primers are specified in Table S4.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, four figures, and four tables and can be found with
this article online at http://dx.doi.org/10.1016/j.stemcr.2016.01.
003.
ACKNOWLEDGMENTS
This work was supported by the Else Kro¨ner-Fresenius Stiftung
(2014_A193), the German Ministry of Education and Research
(BMBF; OBELICS), and the Interdisciplinary Center for Clinical
Research (IZKF) in the Faculty of Medicine at the RWTH Aachen
University (T11-2). Wolfgang Wagner is cofounder of Cygenia
GmbH (www.cygenia.com), which may provide service for the
Epi-MSC-Score and the Epi-Tissue-Score to other scientists.
Received: November 2, 2015
Revised: January 4, 2016
Accepted: January 7, 2016
Published: February 9, 2016
REFERENCES
Bae, S., Ahn, J.H., Park, C.W., Son, H.K., Kim, K.S., Lim, N.K., Jeon,
C.J., and Kim, H. (2009). Gene and microRNA expression signa-
tures of humanmesenchymal stromal cells in comparison to fibro-
blasts. Cell Tissue Res. 335, 565–573.
Bortolotti, F., Ukovich, L., Razban, V., Martinelli, V., Ruozi, G.,
Pelos, B., Dore, F., Giacca, M., and Zacchigna, S. (2015). In vivo
therapeutic potential of mesenchymal stromal cells depends
on the source and the isolation procedure. Stem Cell Rep. 4,
332–339.
Buhring, H.J., Battula, V.L., Treml, S., Schewe, B., Kanz, L., and
Vogel, W. (2007). Novel markers for the prospective isolation of
human MSC. Ann. N. Y. Acad. Sci. 1106, 262–271.
Cai, J., Miao, X., Li, Y., Smith, C., Tsang, K., Cheng, L., and Wang,
Q.F. (2014). Whole-genome sequencing identifies genetic vari-
ances in culture-expanded human mesenchymal stem cells. Stem
Cell Rep. 3, 227–233.
Crisan,M., Yap, S., Casteilla, L., Chen, C.W., Corselli, M., Park, T.S.,
Andriolo, G., Sun, B., Zheng, B., Zhang, L., et al. (2008). A perivas-
cular origin formesenchymal stemcells inmultiple humanorgans.
Cell Stem Cell 3, 301–313.
Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Mar-
ini, F., Krause, D., Deans, R., Keating, A., Prockop, D., and Horwitz,
E. (2006). Minimal criteria for defining multipotent mesenchymalthors
stromal cells. The International Society for Cellular Therapy posi-
tion statement. Cytotherapy 8, 315–317.
Erdmann, G., Suchanek, M., Horn, P., Graf, F., Volz, C., Horn, T.,
Zhang, X., Wagner, W., Ho, A.D., and Boutros, M. (2015). Func-
tional fingerprinting of human mesenchymal stem cells using
high-throughput RNAi screening. Genome Med. 7, 46.
Frobel, J., Hemeda, H., Lenz, M., Abagnale, G., Joussen, S., De-
necke, B., Saric, T., Zenke, M., and Wagner, W. (2014). Epigenetic
rejuvenation of mesenchymal stromal cells derived from induced
pluripotent stem cells. Stem Cell Rep. 3, 414–422.
Garcia, S., Bernad, A., Martin, M.C., Cigudosa, J.C., Garcia-Castro,
J., and de la Fuente, R. (2010). Pitfalls in spontaneous in vitro trans-
formation of human mesenchymal stem cells. Exp. Cell Res. 316,
1648–1650.
Halfon, S., Abramov, N., Grinblat, B., and Ginis, I. (2011). Markers
distinguishing mesenchymal stem cells from fibroblasts are down-
regulated with passaging. Stem Cells Dev. 20, 53–66.
Hematti, P. (2012). Mesenchymal stromal cells and fibroblasts: a
case of mistaken identity? Cytotherapy 14, 516–521.
Holley, R.J., Tai, G.,Williamson, A.J., Taylor, S., Cain, S.A., Richard-
son, S.M., Merry, C.L., Whetton, A.D., Kielty, C.M., and Canfield,
A.E. (2015). Comparative quantification of the surfaceome of
human multipotent mesenchymal progenitor cells. Stem Cell
Rep. 4, 473–488.
Ishii, M., Koike, C., Igarashi, A., Yamanaka, K., Pan, H., Higashi, Y.,
Kawaguchi, H., Sugiyama, M., Kamata, N., Iwata, T., et al. (2005).
Molecular markers distinguish bone marrow mesenchymal stem
cells from fibroblasts. Biochem. Biophys. Res. Commun. 332,
297–303.
Jaenisch, R., and Bird, A. (2003). Epigenetic regulation of gene
expression: how the genome integrates intrinsic and environ-
mental signals. Nat. Genet. Suppl. 33, 245–254.
Karnik, R., and Meissner, A. (2013). Browsing (Epi)genomes: a
guide to data resources and epigenome browsers for stem cell
researchers. Cell Stem Cell 13, 14–21.
Koch, C.M., Suschek, C.V., Lin, Q., Bork, S., Goergens, M., Joussen,
S., Pallua, N., Ho, A.D., Zenke, M., andWagner, W. (2011). Specific
age-associated DNA methylation changes in human dermal fibro-
blasts. PLoS One 6, e16679.
Koch, C.M., Reck, K., Shao, K., Lin, Q., Joussen, S., Ziegler, P.,
Walenda, G., Drescher,W., Opalka, B., May, T., et al. (2013). Plurip-
otent stem cells escape from senescence-associated DNA methyl-
ation changes. Genome Res. 23, 248–259.
Lenz, M., Goetzke, R., Schenk, A., Schubert, C., Veeck, J., Hemeda,
H., Koschmieder, S., Zenke, M., Schuppert, A., and Wagner, W.
(2015). Epigenetic biomarker to support classification into plurip-
otent and non-pluripotent cells. Sci. Rep. 5, 8973.Stem CeReinisch, A., Etchart, N., Thomas, D., Hofmann, N.A., Fruehwirth,
M., Sinha, S., Chan, C.K., Senarath-Yapa, K., Seo, E.Y., Wearda, T.,
et al. (2015). Epigenetic and in vivo comparison of diverse MSC
sources reveals an endochondral signature for human hematopoi-
etic niche formation. Blood 125, 249–260.
Schellenberg, A., Stiehl, T., Horn, P., Joussen, S., Pallua, N., Ho,
A.D., and Wagner, W. (2012). Population dynamics of mesen-
chymal stromal cells during culture expansion. Cytotherapy 14,
401–411.
Shao, K., Koch, C., Gupta, M.K., Lin, Q., Lenz, M., Laufs, S., De-
necke, B., Schmidt, M., Linke, M., Hennies, H.C., et al. (2013).
Induced pluripotent mesenchymal stromal cell clones retain
donor-derived differences in DNA methylation profiles. Mol.
Ther. 21, 240–250.
Sorrentino, A., Ferracin, M., Castelli, G., Biffoni, M., Tomaselli, G.,
Baiocchi, M., Fatica, A., Negrini, M., Peschle, C., and Valtieri, M.
(2008). Isolation and characterization of CD146+ multipotent
mesenchymal stromal cells. Exp. Hematol. 36, 1035–1046.
Squillaro, T., Peluso, G., and Galderisi, U. (2015). Clinical trials
with mesenchymal stem cells: an update. Cell Transplant. http://
dx.doi.org/10.3727/096368915X689622.
Torsvik, A., Rosland, G.V., Svendsen, A., Molven, A., Immervoll,
H., McCormack, E., Lonning, P.E., Primon, M., Sobala, E., Tonn,
J.C., et al. (2010). Spontaneous malignant transformation of hu-
man mesenchymal stem cells reflects cross-contamination: putt-
ing the research field on track—letter. Cancer Res. 70, 6393–
6396.
Wagner, W., Wein, F., Seckinger, A., Frankhauser, M., Wirkner, U.,
Krause, U., Blake, J., Schwager, C., Eckstein, V., Ansorge, W., et al.
(2005). Comparative characteristics of mesenchymal stem cells
from human bone marrow, adipose tissue, and umbilical cord
blood. Exp. Hematol. 33, 1402–1416.
Wagner, W., Feldmann, R.E., Jr., Seckinger, A., Maurer, M.H.,Wein,
F., Blake, J., Krause, U., Kalenka, A., Burgers, H.F., Saffrich, R., et al.
(2006). The heterogeneity of humanmesenchymal stem cell prep-
arations—evidence from simultaneous analysis of proteomes and
transcriptomes. Exp. Hematol. 34, 536–548.
Weidner, C.I., Lin, Q., Koch, C.M., Eisele, L., Beier, F., Ziegler, P.,
Bauerschlag, D.O., Jockel, K.H., Erbel, R., Muhleisen, T.W., et al.
(2014). Aging of blood can be tracked by DNA methylation
changes at just three CpG sites. Genome Biol. 15, R24.
Wuchter, P., Bieback, K., Schrezenmeier, H., Bornhauser, M.,
Muller, L.P., Bonig, H., Wagner, W., Meisel, R., Pavel, P., Tonn,
T., et al. (2015). Standardization of good manufacturing practice-
compliant production of bone marrow-derived human mesen-
chymal stromal cells for immunotherapeutic applications. Cyto-
therapy 17, 128–139.ll Reports j Vol. 6 j 168–175 j February 9, 2016 j ª2016 The Authors 175
